COVID-19 UPDATE: Click here for current news.
The Rx Consultant
 

Keeping health professionals current with useful, quick updates on drugs & therapy - with CE for pharmacists, pharmacy technicians and advanced practice RNs.

Your
Subscription to
The Rx Consultant
Includes:
  • Save Time  | 
  • Stay Current  | 
  • Get CE

Learn what's new with top-selling drugs and common health conditions, & get a quick review. Articles provide context and background in addition to the core information you will use every day.

Meet your state CE requirements and maintain/expand your expertise. 1-2 hours of CE in every issue. Always independently researched & written, with no drug industry money or bias.

Stay up-to-date on the news that matters most & always have answers to key questions at hand.

Quickly check your facts, verify a dose, or give a quick answer with our popular reference cards.

Get the top takeaways from every issue of The Rx Consultant - for an instant update or a quick refresher

Sharpen your patient counseling skills with expert answers to common questions & key counseling points.

Stay ahead of the curve with at-a-glance updates on drugs, doses, common side effects & interactions, indications, treatment guidelines, and more.

50+ hours of current CE on the topics pharmacists, nurse practitioners and pharmacy technicians need to stay current. Get the CE you need today.

 

We do the research, distill the results, consult the experts, and check every fact - so you don't have to.

 
Popular CE Programs
 

1.5  Hours of CE for Pharmacists Advanced Practice RNs & Pharmacy Technicians.

1.5 Hours of ACPE approved CE. Pharmacists, Advanced Practice RNs & Pharmacy Technicians.

1.5 Hours of ACPE approved CE. Pharmacists, Advanced Practice RNs & Pharmacy Technicians.

Our Clients
"The Rx Consultant definitely saves me time. It has the information I need in an easy-to-read format." - W.Gardner
  • Metformin and the Risk of COVID-19 in Women
    People who are obese and/or have diabetes are at risk for severe outcomes from COVID-19. Many of... Read More
  • Use the Extra Dose(s) in Pfizer- BioNTech’s COVID-19 Vaccine Vials
    Pfizer-BioNTech is supplying the US with 200 million COVID-19 vaccine doses by July 31, 2021. Th... Read More
  • PPIs Increase Diabetes Risk
    Chronic use of proton pump inhibitors (PPI) has been linked with a variety of conditions such as... Read More
  • Melatonin Has Not Shown a Clinical Benefit for COVID-19 Management
    In addition to its role in sleep regulation, melatonin reportedly has antioxidant, antiinflammat... Read More
  • PPI Use and COVID-19 RIsk
    Taking proton pump inhibitors (PPIs) may be linked to an increased risk of COVID-19, according ... Read More
  • Pharmacists Authorized to Order & Administer Childhood Vaccines
    In an effort to improve access to childhood vaccines and reduce the risk of preventable diseases... Read More
  • Nearly 90% of Americans live within 5 miles of a community pharmacy. This proximity, in addition to their expertise in drug therapy, puts pharmacists in a unique position to oversee and manage patients’ medications.The pharmacy profession has consistently advocated for expanding the scope of pharmacist's practice to include patient care services beyond the traditional role of dispensing. This expansion includes authorizing pharmacists to prescribe medications.Authorization for pharmacists to prescribe is defined by state regulations, federal agencies (eg, Indian Health Service [IHS], Veterans Health Administration [VHA]), employers, and professional organizations.At the state level, a number of advances have been made that provide pharmacists with limited prescriptive authority.

    Although almost every state authorizes pharmacists to prescribe to some extent, the models and restrictions vary – leading to considerable state-to-state variability. As of 2016, 49 states and the District of Columbia had enabled prescriptive authority under collaborative practice agreements (CPAs), standing orders, and/or statewide protocols.

    Currently, pharmacist prescribing at the state level generally exists along a continuum that includes 2 categories of prescriptive authority.
  • Four decades after the first case of acquired immunodeficiency syndrome (AIDS) was reported, 38 million people are living with HIV worldwide.Over the last two decades, significant progress has been made in battling the disease. Since peaking in 1997, the number of new cases has decreased 40% worldwide and since 2004, AIDS-related deaths have declined more than 56%.In the US, just over 1 million people are living with HIV and new infections declined 11% between 2010 and 2017.

    The number of people living with HIV has increased since the late 1990s due to the availability of potent and better tolerated antiretrovirals (ARVs) that prolong life. People in the 50 to 54 year old age group account for the largest percentage of those living with HIV in the US.Individuals with HIV now have a similar life expectancy as the general population.However, complete viral suppression with antiretroviral therapy (ART) does not fully restore health. Deaths due to non-AIDS related complications range from 18.5% in sub-Saharan countries to 53% in high-income countries. These include cardiovascular,kidney, and liver diseases, as well as various types of cancer and neurologic disorders often linked with aging. Metabolic complications including dyslipidemia and type 2 diabetes can also occur.“Premature aging” of people with HIV is believed to result from persistent viral inflammation rather than toxicity from ARV therapy.

    This issue reviews recommended ARVs and focuses on the initial management of HIV in treatment-naïve adults, according to guidelines provided by the Department of Health and Human Services (DHHS). In addition, recommendations for ART in pregnancy are summarized and an update is included on the use of ARVs for PrEP and post-exposure prophylaxis (PEP), according to guidelines provided by the CDC.
  • There has been an increase in prescription medications, mainly stimulants, for the treatment of attention deficit hyperactivity disorder (ADHD) along with an explosion of new formulations. A 2016 CDC report estimates that about 9% of children 2 to 17 years of age (6.1 million) have been diagnosed with ADHD. Among the children with ADHD, 6 out of 10 were taking ADHD medication. The lifetime prevalence of ADHD has been estimated to be as high as 8.1%. In 2015, 4% of privately insured women ages 15 to 44 filled an ADHD prescription, most often for a stimulant such as mixed amphetamine salts or methylphenidate – a 344% increase compared to 2003.3 In 2016, the CDC reported that 3 out of 4 preschoolers diagnosed with ADHD were prescribed stimulants, despite a recommendation for behavior therapy alone for that age group.

    This issue is the first of a 2-part review of ADHD. Part 1 focuses on stimulant and nonstimulant treatments for ADHD, including the advantages of certain formulations and delivery methods, common and serious adverse effects, and possible longterm effects. Part 2 is available online at rxconsultant.com and summarizes diagnosis and clinical presentation in all age groups (including adults), non-drug and behavioral interventions, clinically significant drug interactions with stimulants and nonstimulants, and the comorbid conditions that often accompany ADHD.


  • This issue highlights the use of continuous glucose monitoring (CGM) systems, sodium glucose transport protein-2 (SGLT2) inhibitors, newer insulin formulations, and the expert guideline recommendations focused on individualization of therapy.

    In 2017, the Centers for Disease Control reported that over 30 million people in the US (~10% of the population) have diabetes, including 7.2 million who are undiagnosed. The total estimated cost of diagnosed diabetes in the US was $327 billion in 2017.2 Individuals with diabetes incur average annual medical expenses of about $16,750 – more than twice the expense for people without diabetes.

    Over the last decade, the options for managing diabetes have grown dramatically – including new medication classes (eg, glucagon- like peptide-1 agonists, sodium-glucose transport protein-2 inhibitors), new insulin analogs (eg, insulin degludec, biosimilar insulins), and new technologies to help patients monitor their diabetes (eg, continuous glucose monitoring).

    Clinical practice guidelines have increased the emphasis on individualizing treatment options and goals to meet the needs of each patient. Patients have more say in the management of their diabetes and overall health. It is essential that healthcare providers help patients navigate the vast pool of information available at their fingertips. Diabetes patients can easily get confused by the often-conflicting information or misinformation available on television and the internet, and from friends and family members. Community providers need a good, working knowledge of patient-specific diabetes management, including current treatments and technologies...

 
ACPE logo

Pharmacists: Continuing Education Network, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Advanced Practice Nurses : (Nurse Practitioners and Clinical Nurse Specialists): CE hours provided by Continuing Education Network (in The Rx Consultant) meet the ANCC criteria and the AANP criteria for formally approved continuing education hours. Click here for more information about the ANCC criteria. Click here for more information about the AANP criteria.

Registered Nurses : Click here for specific information on acceptance of CE from The Rx Consultant by your state Board of Registered Nursing.